* More than 25 years of experience* Clinical Director of Haemato-Oncology, Worcestershire Acute NHS Trust (Teaching) * Consultant Haematologist, BMI Priory Edgbaston (present)* â‚¬â€¹Consultant Haematologist, BMI The Droitwich Spa Hospital (present)* Consultant Haematologist, Spire Southbank, Worcester (present)* Clinical Trial Experience, Chief Trial Haematology Lead for Worcestershire Acute Trust (present)* Consultant TDL laboratory staff, BMI Priory Hospital in Birmingham (present) ...

* FRCPath (Haematology) Royal Collge of Pathology, London (2002)* FRCP (Edinburgh) Royal College of Physicians, Edinburgh (1999) * FRCP Royal College of Physicians, London (1998)* DipRCPath Royal College of Pathology (1997)* MD University of Calicut, Kerala (1989) ...

* Member of British and American Society of Haematology* Fellow of Royal College of Physicians, London and Edinburgh * Fellow of Royal College of Pathology, London* Member of UK Myeloma Forum* Member of UK CLL Forum* Member of UK Thromboprophylaxis Forum* Member of British Society for Haematology* Member of Associations of Physicians, India ...

* Prof G.K.Warrier Memorial Gold Medal, Best Out Going Postgraduate Student (1992)* Indian Association of Paediatrics Quiz, runner-up (1987) * Clinical Excellence Awards (CEA) - Level 9 (Equivalent to Bronze nationally) ...

* Has published many articles in peer-reviewed journals.* Reviewer for Cancer Peer Review. * Presents both nationally and internationally.* DEFINING THE DOSE OF GEMTUZUMAB(OZOGAMICIN) IN AML A COMPARITIVE RANDOMISED STUDY MRC AML 17 TRIAL. ALAN BURNETT, JAMIE CAVENAGH, NIGEL RUSSELL ET AL €“ ACKNOWLEDGEMENT SALIM SHAFEEK (WORCESTERSHIRE ROYAL TRUST. HAEMATOLOGICA FEB 2016* ADDITION OF GEMTUZUMAB (OZOGAMICIN) TO INDUCTION CHEMOTHERAPY IMPROVES SURVIVAL IN OLDER PATIENTS WITH AML-MRC AML TRIAL DATA- JCO 30TH JULY 2012 PROF ALAN BURNETT, CHARLIE CRADDOCK, DON MILLIGAN ET AL €“ ACKNOWLEGEMENT €“SALIM SHAFEEK (WORCESTERSHIRE ROYAL HOSPITAL)* PROSPECTIVE MRD MONITORING TO PREDICT RELAPSE OF APML and TO DIRECT PREEMTIVE ARSENIC TRIOXIDE TREATMENT €“MRC AML 15 TRIAL PROF DAVID GRIMWADE ET AL €“ ACKOWLEDGEMENT SALIM SHAFEEK (WORCESTERSHIRE ROAYL HOSPITAL) JCO 9TH FEB 2009* FIRST-LINE TREATMENT WITH ZOLEDRONIC ACID AS COMPARED WITH ORAL CLODRONATE IN MULTIPLE MYELOMA(MRC MYELOMA IX) AS RANDOMISED CONTROLLED TRIAL: LANCET 376 (0757) PP 1989-1999 GARETH MORGAN , FAITH DAVIES ET AL- SALIM SHAFEEK (WORCESTESHIRE ROYAL HOSPITAL)* Image in Blood Med. Pamidronate induced osteonecrosis of the jaw in a myeloma patient. S.Paneesha,S.Shafeek,N.Barnard,U.Udeshi. https://www.bloodmed.com/education/case1.asp?id=194.* Image in Blood Med. Variant acute promyelocytic leukaemia presenting with massive intracerebral haemorrhage. S Paneesha, S Shafeek, C Phillips and R Stockley https://www.bloodmed.com/education/case1.asp?id=195.* CLIMATIC INFLUENCE ON HAEMOGLOBIN LEVELS OF BLOOD DONORS. SHAFEEK S, BECKMAN N. SMITH N, GABRA G, TRANSFUSION TODAY, NO. 28. SEPTEMBER 1996, PAGE 6-8.* TREATMENT OF ANAEMIA OF PROGRESSIVE RENAL FAILURE WITH RECOMBINANT ERYTHROPOIETIN - A PRELIMINARY REPORT. SALIM K.A, SHAFEEK S, MATHEW T.J.ASSO PHYSICIANS OF INDIA, VOL 40, PAGE 42-3, JANUARY 1992.* CHICKENPOX INDUCED PANCYTOPENIA AND PROMPT RESPONSE TO HIGH DOSE INTRAVENOUS IMMUNOGLOBULIN. SHAFEEK. S, SALIM K.A, JAPI, VOL 40, NO. 10: PAGE 689-690 1992.* ANTIPHOSPHOLIPID ANTIBODY SYNDROME OF SLE PRESENTING AS DEEP THROMBOSIS. SHAFEEK.S,SALIM.K.A. JAPI,FEBRUARYL992,VOL4O,NO2,PAGE 125-126.* NON-HODGKIN'S LYMPHOMA PRESENTING AS PURE RED CELL APLASIA. SHAFEEK S, SALIM.K.A, JAPI, VOL. 40. NO. 11. PAGE 765 - 766. 1992* The Quadruplet Combination of Carfilzomib, Cyclophosphamide , Lenalidomide and dexamethasone is safe and well tolerated as induction therapy for Newly diagnosed , transplant eligible Myeloma patients (Myeloma XI+ trial UK) Faith Davies , Nigel Russell, Gordon Cook , Donald Milligan , Salim Shafeek , Gareth Morgan et al EHA 12th June 2015 Oral presentation.* The UK and Ireland Perspective of Relapsed refractory Multiple Myeloma(PASS) treated with Lenalidomide, Bortezomib and Thalidomide. Multicenter Observational PASS study. Poster EHA 2014 Jenny Bird, Salim Shafeek, John Ashcroft, Roger Owen and Graham Jackson* Toxicity and Efficacy of Bendamustine in CLL and Indolent NHL €“ A Multicenter observational of real life experience in UK. Poster EHA 2015 Duncan Murray, Supratik Basu, Salim Shafeek, Sridhar Chaganti, Shankara Paneesha and Sebastian Francis* High dose ARA-C/Amsacrine as salvage therapy in Acute leukaemias- Regional transplant centre experience .S. Paneesha, S.Shafeek, P.Mahendra, C.Craddock.(BSH Poster - April 2002 )* Two cases of Post Transfusion Hyperhaemolysis in Sickle cell disease. S.Shafeek, M.Jabbar, M.J.Strevens,D.Bareford ,N.Smith ;British Journal of Haematology ,Suppl 1 March 2000: Page 38.* A baby with combined hyperlipidaemia presenting as Anaemia and Milky Blood Salim K.A. Shafeek S, Blood Vol 76, No. 10: 46a. Suppl: November 15th 1990* A case of haemolysis due to excess serum copper possibly from dietary sources in a patient having Low serum Caeruloplasmin. Salim K.A, Shafeek.S. Blood Vol 76, No 10, 46a, suppl: Nov 15th 1990.* Effect of short course Alpha Interferon in chronic myelogenous leukaemia. Salim K.A, Shafeek S, Sathianathan P. Abstract €“ British Joumal of Haematology, August 1992 (ISH Special)* An unusual case of eosinophilic granuloma (Langerhans Cell Granuloma) -1991 - API Agra, India. Salim K.A, Shafeek S. Presented at Asso Physicians of India National Conference.* Ondansetron versus high dose metoclopramide in Chemotherapy induced nausea and vomiting - A preliminary report. Salim K.A., Shafeek. S, Sathyanathan P. Presented at API National Conference April 1992.* Mucor Mycotic Osteitis and Rhinocerebral mucormycosis in a diabetic patient with Diabetiv Ketoacidosis. Shafeek, Salim KA- Presented at API meeting,April1992* A clinical profile of acute intermittent Porphyria - twelve cases. Salim K.A, Shafeek. S, Sathyanathan P, Paper Presented at API January 1993.* An unusual case of systemic amyloidosis and plasma cell dyscrasia in a 62 year old man. Salim K.A., Shafeek S., Sathyanathan P. Paper presented for API, January 1993.* Pseudotumour of right leg in a patient with haemophilia - A. Salim K.A. Shafeek, Sathyanathan P, paper presented for API January 1993.* Effect of ondansetron (5H3 receptor antagonist) in the relief of symptoms in malignant Carcinoid syndrome. Salim. K.A., Shafeek. S, Manoj. C. Paper presented for API January 1992.* Clinical effect of octreotide (Sandostatin) in controlling the symptoms of Malignant carcinoid syndrome. Salim. K.A, Shafeek. S, Manoj. S. Paper presented for API January 1993.* Lymes Disease - Calicut Experience. Salim. K.A, Shafeek. S. Sathyanathan. P. Paper presented for API January 1993.* Lenalidomide Induction and Maintenance for Transplant-Eligible Patients of All Ages with Newly Diagnosed Multiple Myeloma (2018) ...

* Principal Investigator for National Clinical Trials (NCRI-UK)

* Senior Lecturer in Clinical Haematology, University of Birmingham (present)* Medical Advisory Panel for treatment in CLL (2009) * Examiner MRCP Paces for Royal College of Physicians (2008 - present)* Examiner for Royal College of Pathology* Offers courses to GPs ...